William Spreen

9.3k citations

80 papers · 3.6k indexed · 1 hit paper · h-index 30

Infectious Diseases top 0.5%
Virology top 0.2%
Epidemiology top 5%
Pharmacology top 2%
Immunology top 10%

Co-authors: Susan L. Ford David A. Margolis Stephen C. Piscitelli Arlene R. Hughes John C. Pottage Michael Mosteller Eric Lai Elizabeth Gould
Topics: HIV/AIDS drug development and treatment (59 papers)HIV Research and Treatment (52 papers)HIV/AIDS Research and Interventions (38 papers)
Cited by: Virology Infectious Diseases Emergency Medicine
Journals: Science The Lancet Nature Medicine
Partner nations: United States United Kingdom Belgium

In The Last Decade

William Spreen

79 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

2002 583 citations Seth Hetherington, Arlene R. Hughes et al. profile →

Peers

Countries citing papers authored by William Spreen

Since Specialization

Citations

This map shows the geographic impact of William Spreen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Spreen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Spreen more than expected).

Fields of papers citing papers by William Spreen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Spreen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Spreen. The network helps show where William Spreen may publish in the future.

Co-authorship network of co-authors of William Spreen

This figure shows the co-authorship network connecting the top 25 collaborators of William Spreen. A scholar is included among the top collaborators of William Spreen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Spreen. William Spreen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1 2025 ·AIDS ·Ronald D’Amico,Kelong Han,Sherene Min,(unknown),(unknown),Susan L. Ford,Conn Harrington,Enrique Bernal,Johannes Lombaard,Herta Crauwels,(unknown),(unknown),(unknown),Rodica Van Solingen‐Ristea,(unknown),William Spreen	1
2	SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity 2024 ·Nature Communications ·Michele B. Daly,Chuong Dinh,Angela Holder,Donna L. Rudolph,Susan Ruone,(unknown),George Khalil,Sunita Sharma,(unknown),(unknown),(unknown),Yi Pan,Kelly A. Curtis,(unknown),William Spreen,Walid Heneine,J. Gerardo Garcı́a-Lerma	0
3	Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study 2024 ·AIDS and Behavior ·Cristina Mussini,Charles Cazanave,Eisuke Adachi,(unknown),Marta Montero,Gordon Crofoot,Vasiliki Chounta,(unknown),Kenneth Sutton,Denise Sutherland‐Phillips,(unknown),(unknown),(unknown),Patricia Rios,Ronald D’Amico,William Spreen,Jean van Wyk	3
4	Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide 2024 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Darrell H. S. Tan,(unknown),(unknown),(unknown),Clifford Kinder,(unknown),Cornelius N. Van Dam,Kenneth Sutton,Denise Sutherland‐Phillips,Alessandro Berni,Feifan Zhang,(unknown),Bryan Baugh,William Spreen,(unknown),H Garges,Parul Patel,Rachel L. Batterham,Ronald D’Amico	4
5	2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies 2019 ·Open Forum Infectious Diseases ·Parul Patel,Susan L. Ford,Herta Crauwels,Kelong Han,Stefaan Rossenu,(unknown),Sandy Griffith,Krischan J Hudson,David M. Margolis,Mark Baker,Peter Williams,William Spreen	17
6	Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial 2018 ·HIV Clinical Trials ·Miranda Murray,Martin Markowitz,Ian Frank,Robert M. Grant,Kenneth H. Mayer,Krischan J Hudson,Britt Stancil,Susan L. Ford,Parul Patel,Alex R. Rinehart,William Spreen,David A. Margolis	54
7	Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial 2017 ·The Lancet HIV ·Martin Markowitz,Ian Frank,Robert M. Grant,Kenneth H. Mayer,Richard Elion,Deborah Goldstein,(unknown),Magdalena E. Sobieszczyk,Joel E. Gallant,Hong‐Van Tieu,Winkler G. Weinberg,David A. Margolis,Krischan J Hudson,Britt Stancil,Susan L. Ford,Parul Patel,Elizabeth Gould,Alex R. Rinehart,Kimberly Y. Smith,William Spreen	164
8	Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251 2016 ·AIDS ·Chasity D. Andrews,(unknown),(unknown),Hiroshi Mohri,(unknown),William Spreen,Agegnehu Gettie,Kasi Russell‐Lodrigue,James Blanchard,Zhi Hong,David D. Ho,Martin Markowitz	33
9	Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial 2015 ·The Lancet Infectious Diseases ·David A. Margolis,Cynthia Brinson,Graham Smith,Jerome De Vente,Debbie Hagins,Joseph J. Eron,Sandy Griffith,M H St Clair,Marita Stevens,Peter Williams,Susan L. Ford,Britt Stancil,(unknown),Krischan J Hudson,Kimberly Y. Smith,William Spreen	157
10	Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus 2014 ·Science ·Chasity D. Andrews,William Spreen,Hiroshi Mohri,(unknown),Susan L. Ford,Agegnehu Gettie,Kasi Russell‐Lodrigue,Rudolf P. Bohm,Cecilia Cheng‐Mayer,Zhi Hong,Martin Markowitz,David D. Ho	120
11	GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects 2014 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·William Spreen,Susan L. Ford,Shuguang Chen,David Wilfret,David M. Margolis,Elizabeth Gould,Stephen C. Piscitelli	117
12	Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults 2014 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·William Spreen,Peter Williams,David M. Margolis,Susan L. Ford,Herta Crauwels,Yu Lou,Elizabeth Gould,Marita Stevens,Stephen C. Piscitelli	96
13	Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor 2013 ·HIV Clinical Trials ·William Spreen,Sherene Min,Susan L. Ford,(unknown),Yu Lou,(unknown),Marty St. Clair,(unknown),Tamio Fujiwara	92
14	Long-acting injectable antiretrovirals for HIV treatment and prevention 2013 ·Current Opinion in HIV and AIDS ·William Spreen,David A. Margolis,John C. Pottage	206
15	A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen 2010 ·HIV Clinical Trials ·Scott M. Hammer,Heather J. Ribaudo,Roland Bassett,John W. Mellors,Lisa M. Demeter,Robert W. Coombs,Judith S. Currier,Gene D. Morse,John G. Gerber,Ana I. Martínez,William Spreen,Margaret A. Fischl,Kathleen Squires,(unknown)	16
16	A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen 2010 ·HIV Clinical Trials ·Scott M. Hammer,Heather J. Ribaudo,Roland Bassett,John W. Mellors,Lisa M. Demeter,Robert W. Coombs,Judith S. Currier,Gene D. Morse,John G. Gerber,Ana I. Martínez,William Spreen,Margaret A. Fischl,Kathleen Squires	12
17	Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility 2008 ·The Pharmacogenomics Journal ·Arlene R. Hughes,William Spreen,Michael Mosteller,Liling Warren,Eric Lai,Cynthia H. Brothers,Charles Cox,Anita J. Nelsen,Scott Hughes,D. Thorborn,Britt Stancil,Seth Hetherington,Daniel K. Burns,A D Roses	61
18	Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects with Prior Nucleoside Analog Experience 2008 ·HIV Clinical Trials ·Lisa M. Demeter,Victor DeGruttola,Stephanie Lustgarten,(unknown),Margaret A. Fischl,Susan H. Eshleman,William Spreen,Bach-Yen Nguyen,Christine Koval,Joseph J. Eron,Scott Hammer,Kathleen Squires	13
19	Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase 2000 ·AIDS ·Michael M. Lederman,Ray A. McKinnis,Dennis Kelleher,Amy Cutrell,John W. Mellors,(unknown),Elizabeth Cooney,David W. Haas,Richard Haubrich,James Stanford,James Horton,Alan Landay,William Spreen	69
20	Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy 2000 ·AIDS ·Pierre‐Alexandre Bart,Gian Paolo Rizzardi,Giuseppe Tambussi,(unknown),Aude G. Chapuis,Cecilia Graziosi,Jean-Marc Corpataux,Nermin Halkic,Jean‐Yves Meuwly,Miguel Muñoz,Pascal Meylan,William Spreen,Hugh McDade,Sabine Yerly,Luc Perrin,Adriano Lazzarin,Giuseppe Pantaleo	56

About William Spreen

William Spreen is a scholar working on Virology, Infectious Diseases and Hepatology, having authored 80 papers that have together received 3.6k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (59 papers), HIV Research and Treatment (52 papers) and HIV/AIDS Research and Interventions (38 papers). The work is most often cited by research in Virology (1.8k citations), Infectious Diseases (2.4k citations) and Emergency Medicine (344 citations). William Spreen has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include Susan L. Ford, David A. Margolis, Stephen C. Piscitelli, Arlene R. Hughes, John C. Pottage, Michael Mosteller, Eric Lai, Elizabeth Gould, Allen D. Roses and David M. Margolis. Their work appears in journals such as Science, The Lancet and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact